Genor Biopharma Holdings Limited (the “Company,” Stock Code: 6998) released an announcement dated 27 October 2025 detailing updates on a series of contemplated transactions, including a Very Substantial Acquisition and Connected Transaction, a Reverse Takeover involving a new listing application, a Whitewash Waiver application, a Special Deal regarding the retention plan of shareholder personnel, a proposed change of company name, an increase in authorized share capital, and the adoption of a One-Off Share Option Plan.

According to the announcement, the Company submitted its New Listing Application on 15 April 2025. The dispatch date of the related circular, previously extended to on or before 31 October 2025, has now been further delayed to on or before 30 November 2025 to allow additional time for addressing regulatory comments.

The announcement reiterates that the closing of the proposed merger depends on the satisfaction or waiver of certain prerequisites, including the Whitewash Waiver and approval of the New Listing Application by the Stock Exchange. It cautions that should these provisions not be met, the proposed merger will not proceed. The announcement also reminds shareholders and potential investors to exercise caution when dealing in the Company’s shares.